Aim: To evaluate markers of mast cell and basophil activation in children undergoing the initial phase of honeybee venom immunotherapy (VIT). Patients & methods: Five children (four boys and one ...

The mast cells in mastocytosis accumulate in tissues that generally release more mediators (histamine, cytokines, and proteases). The number of basophils, which can react like mast cells ...

PRESS RELEASEAB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

Mast cell activation syndrome (MCAS) is a condition in which mast cells—a type of white blood cell that plays a key role in ...

Research into the origins of sepsis has identified a type of rare white blood cell, basophils, as a potentially key component in preventing the development of the condition. What is the basophils ...

Innate immune cells are white blood cells that mediate innate immunity and include basophils, dendritic cells, eosinophils, Langerhans cells, mast cells, monocytes and macrophages, neutrophils and ...

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announced that the European Patent Office has issued a Notice of ...

Only heparin is stored intracellularly, chiefly in mast cells and basophils. Little is known of its metabolism in humans, although rat tissues rapidly take it up after injection 1. Although in ...

Mediators of mast cells and basophils provoke interest as potential markers of anaphylactic reactions that may be useful both in the diagnosis of venom allergy and monitoring venom immunotherapy.

Standard treatment for SCD includes red blood cell transfusions and treatment with hydroxyurea to manage complications, but significant unmet need remains. Mast cells, a major target for ...

Standard treatment for SCD includes red blood cell transfusions and treatment with hydroxyurea to manage complications, but significant unmet need remains. Mast cells, a major target for masitinib, ...